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Abstract 
 
Duchenne muscular dystrophy (DMD) is a rare genetic disease affecting 1 in 3500-5000 newborn 
boys. It is due to mutations in the DMD gene with a consequent lack of dystrophin protein that leads 
to deterioration of myofibres and their replacement with fibro-adipogenic tissue. Out-of-frame 
mutations in the DMD gene can be modified by using antisense oligonucleotides (AONs) to promote 
skipping of specific exons such that the reading frame is restored and the resulting protein produced, 
though truncated, is functional. We have shown that AONs can also be used to knock down 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz125/5513018 by R
oyal H
ollow
ay, U
niversity of London user on 19 June 2019
2 
 
myostatin, a negative regulator of muscle growth and differentiation, through disruption of the 
transcript reading frame, and thereby enhance muscle strength. In young mdx mice, combined 
dystrophin and myostatin exon skipping therapy greatly improved DMD pathology, compared to the 
single dystrophin skipping approach. Here we show that in aged (> 15-month old) mdx mice, when 
the pathology is significantly more severe and more similar to the one observed in DMD patients, the 
effect of the combined therapy is slightly attenuated but still beneficial in improving the disease 
phenotype. These results confirm the beneficial outcome of the combination approach and support its 
translation into DMD clinical trials. 
 
Introduction 
Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease affecting 1 in 3500-5000 
newborn boys worldwide (1). It is due to mutations in the DMD gene coding for dystrophin protein 
that connects the cytoplasmic actin to the dystrophin associated protein complex at the sarcolemma of 
the myofibres (2, 3). Loss of dystrophin in the sarcolemma weakens the stability of the myofibres 
such that they are prone to collapse. Muscle turn-over occurs during initial stages of the disease by 
activation, proliferation and differentiation of muscle stem cells (3, 4). Over time the pool of muscle 
stem cells is exhausted leaving muscle tissue being replaced by adipogenic and connective tissues (5). 
No cure is currently available for this genetic disease and therefore, individuals affected by DMD 
generally die in their mid-20s to early 30s mainly due to cardiac and respiratory failure (6).  
 
Lack of dystrophin due to frameshift mutations can be modified by the use of antisense 
oligonucleotides (AONs). These molecules are designed to target regulatory elements of out-of-frame 
exons in the dystrophin pre-mRNA to restore the DMD reading frame and recover production of 
dystrophin protein, in a truncated but functional form (7). Sarepta Therapeutics, Inc. currently leads 
clinical trials using phosphorodiamidate morpholino oligomer (PMO) AONs. Their antisense 
therapeutics for exon 51 (Eteplirsen) of the DMD gene received an accelerated conditional approval 
from the Food and Drug Administration in 2016 
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 (https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm). While an exon 
skipping approach has exciting potential, it is mutation specific and thereby different AONs are 
required to target different exons. Furthermore, the efficacy of AONs has been hampered by their 
modest intake by the muscle tissue (in particular the cardiac muscle). Hence, several strategies 
developing AONs to be conjugated to cell-penetrating peptides, aptamers or antibodies have been 
explored, significantly improving the uptake of AONs into the tissues (8–11).  
 
Antisense therapeutics have been also developed to knock-down expression of myostatin, a member 
of the TGF-β family and a negative regulator of muscle growth and differentiation (12). Since 
myostatin knockout animals display a significant increase in muscle mass (12–14), many anti-
myostatin strategies have been studied as therapeutic approaches for the treatment of diseases where 
muscle mass is reduced; for example, cancer-induced cachexia, sarcopenia, or muscle atrophy due to 
neuromuscular and neurological diseases (e.g. DMD, spinal muscular atrophy, amyotrophic lateral 
sclerosis). In preclinical approaches for DMD, systemic delivery of AAVs expressing pro-peptide for 
myostatin or delivery of myostatin-specific antibodies has shown encouraging results with a 
substantial increase in muscle mass (15–17).  
 
We have recently reported that combining antisense therapeutics re-framing dystrophin while 
disrupting myostatin pre-mRNA has a synergistic effect in improving the disease (18, 19). Significant 
benefit was observed when AONs were systemically administered in both newborn (18) and juvenile 
mdx mice (19), the most used animal model of DMD where a point mutation in exon 23 of the murine 
Dmd gene prevents production of dystrophin protein (20). The mdx mouse model is a valuable tool 
and widely used to test in vivo approaches for DMD. However, the DMD phenotype is better 
reproduced on these animals when mice are more than 10-12 months old. From this stage onwards, 
cardiac and skeletal muscles (in particular the diaphragm) are remarkably dysfunctional due to severe 
infiltration by fibrotic and inflammatory cells (21). However, no studies have yet investigated the 
effect of dystrophin restoration by exon skipping in these aged mdx mice.  
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Here we compare the combination of dystrophin and myostatin exon skipping with the single 
dystrophin exon skipping in aged (> 15-months old) mdx mice. We report our findings following 10-
weekly intravenous delivery of PMOs linked to a cell-penetrating B peptide (BPMOs) and provide 
evidence to support that simultaneous exon skipping-mediated myostatin downregulation has an 
additive impact on dystrophin restoration and on muscle function of treated mice. 
 
Results 
Chronic administration of antisense oligonucleotides targeting dystrophin and myostatin in 
aged mdx mice induces high levels of dystrophin expression 
Aged (>15-month old) male mdx mice were intravenously injected with phosphorodiamidate 
morpholino oligomers (PMOs) conjugated to a cell-penetrating peptide (B-peptide). Mice received 
weekly injections of either 10 mg/kg BPMO-M23D targeting dystrophin (n=5) or a cocktail of 10 
mg/kg BPMO-M23D and 10 mg/kg BPMO-MSTN targeting myostatin (BPMO-M23D+MSTN, n=5) 
for 10 consecutive weeks to potentially allow a substantial and consistent amount of dystrophin 
restoration. Age-matched saline-treated mdx (n=6) and C57BL/10J mice (n=6) were used as controls. 
All mice survived until the end of the experiment. Body weight of mice measured every week, 
showed that at this age the weight in both dystrophic and wild-type mice tended to decrease over time. 
Mdx mice lost 2.9±0.6 grams of body weight after the 10-week treatment while administration of 
either BPMO-M23D or the combination of the BPMOs significantly reduced the loss of body weight 
(losing 1.3±0.2 and 1.8±0.2 grams, p<0.01 and p<0.05 respectively, Figure 1A). Two weeks after the 
last injection, body-wide muscles were harvested and weighed. Mdx muscles present 
pseudohypertrophy due to myofibre branching and inflammation and were heavier than wild-type 
muscles with the ratio muscle weight/body weight significantly higher in mdx mice versus C57 mice 
for diaphragm (DIA, 4.2±0.1 vs 3.5±0.1, p<0.05), extensor digitorum longus (EDL, 0.47±0.04 vs 
0.35±0.01, p<0.05), soleus (SOL, 0.46±0.02 vs 0.29±0.01, p<0.001) and tibialis anterior (TA, 2.4±0.1 
vs 1.5±0.02, p<0.001), while no difference was observed in the gastrocnemius muscle (GAS,  
4.96±0.14 vs 4.9±0.1, p>0.05). Treatment with either BPMO-M23D or the combined BPMOs did not 
substantially change the muscle weight of mdx DIA (4.2±0.11 and 4.1±0.15 respectively), EDL 
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(0.48±0.04 and 0.52±0.02 respectively), GAS (4.30±0.38 and 4.26±0.30 respectively), SOL 
(0.38±0.02 and 0.42±0.02 respectively) or TA (2.46±0.13 and 2.56±0.15 respectively), as compared 
to muscles of saline-treated mdx mice (Figure 1B). Two weeks after the last injection, DIA, EDL, 
GAS, SOL, TA, and heart muscles were collected and processed for RNA and protein extraction. 
Densitometric analysis of nested RT-PCR products was performed in all these skeletal and cardiac 
muscles. Consistent Dmd exon 23 skipping was observed in all skeletal muscles following BPMO-
M23D delivery, ranging from 35.4±1.4% (DIA) to 60.4±3.4% (TA) of the total transcript. 
Administration of BPMO-M23D+MSTN led to an increase in skipping efficiency from 46.6±0.7% to 
59.4±1.0% (p < 0.0001), as an average of all muscles analysed, with the highest enhancement 
observed in DIA (from 35.4±1.4% to 61.2±3.9%, p=0.0003) and a notable increase in the heart (from 
16.4±1.6% to 27.0±1.6%, p=0.0016) (Figures 2A, B). Dystrophin protein restored as a result of the 
treatments was measured by immunoblot and expressed as the percentage of wild-type dystrophin 
quantified based on serial concentrations of C57BL/10J dystrophin protein (Figures 2C, D). BPMO-
M23D delivery rescued 4.1±2.0% body-wide dystrophin, with an exceptional maximal level of 
13.1±3.7% in SOL. In DIA and heart, dystrophin was detected at lower amounts (1.5±1.5% and 
4.8±0.6%, respectively) but only when BPMO-MSTN was co-delivered. Administration of BPMO-
M23D+MSTN increased body-wide level of dystrophin from 4.1±2.0% to 9.8±3.0% (p=0.001), and 
significantly improved the level in TA muscle (from 5.0±1.2% to 21.0±3.2%, p=0.0015) (Figure 2D). 
To complement the results obtained by western blot, we performed co-immunostaining for dystrophin 
and laminin in two crucial muscles, TA and DIA (Figure 2E). BPMO treated muscles showed 
dystrophin expression clearly distinguishable compared to the background of saline treated muscles 
and with patches of fibres expressing higher dystrophin levels. The percentage of such dystrophin 
positive fibres relative to total fibres (laminin positive) was quantified, confirming 35.2±2.2% and 
12.9±0.6% fibres rescued in TA and DIA, respectively after BPMO-M23D administration. Co-
delivery of BPMO-M23D and BPMO-MSTN increased the percentage of dystrophin positive fibres to 
44.1±2.2% (p<0.01) in TA and 32±3% (p<0.001) in DIA (Figures 2F, G). 3.4±0.3% dystrophin 
positive fibres were observed in saline-treated muscles.  
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These data show that aged mdx mice generally lose body weight overtime and that the treatment with 
either BPMO-M23D or the BPMO combination reduce this bodyweight loss although no effects are 
observed in muscle weight. Furthermore, these data demonstrate that systemic delivery of BPMO-
M23D induces a substantial skipping of dystrophin exon 23 accompanied by the production of 
dystrophin protein in aged mdx mice. Co-delivery of BPMO-M23D+MSTN significantly enhances 
exon skipping levels and increases dystrophin protein production.  
 
Delivery of BPMOs for dystrophin and myostatin exon skipping in aged mdx mice induces 
detectable MSTN skipping bodywide and decrease of MSTN mRNA in diaphragm 
Following densitometric analysis of nested RT-PCR products, we detected skipping of Mstn exon 2 in 
all the examined tissues at an average of 19.6±2.7%, with the lowest amount in GAS (10.4±1.1%) and 
the highest in DIA (35.4±11.9%) (Figures 3A, B). In order to assess the efficacy of the treatment in 
myostatin expression we performed an ELISA assay on sera of treated mice and quantitative real-time 
RT-PCR in TA and DIA muscles. Saline-injected mdx mice expressed significantly less circulating 
myostatin protein than wild type mice as expected, p=0.0002 (22) (Figure 3C). Analysis of Mstn 
mRNA via qRT-PCR consistently confirmed that the mRNA level in both DIA and TA muscles of 
aged mdx mice expressed significantly less Mstn compared to the wild type levels, p<0.0001 and 
p=0.0365 respectively. Although we did not detect any significant change between the mdx groups in 
either myostatin protein or mRNA level, only dystrophic TA muscles receiving BPMO treatment 
displayed a similar amount of Mstn RNA compared to wild type muscles (Figures 3D, E).  
 
These data show that BPMO-MSTN induces detectable body-wide skipping of Mstn pre-mRNA 
although with different efficacy among muscles. 
 
Dystrophin and Myostatin exon skipping ameliorates histopathological features of DMD and 
protects muscles of aged mdx mice  
Dystrophic muscles are affected by muscle necrosis that induces myofibre turn-over, excessive 
fibrosis deposition and muscle weakness. Thereby, we analysed the effect of the chronic systemic 
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administration of BPMOs on DMD physiopathology based on these parameters. Repeated tissue 
degeneration-regeneration cycles were examined by measuring the number of centrally nucleated 
fibres (CNFs), expressed as percentage of the total fibre number. Co-staining of laminin (for myofibre 
sarcolemma) and DAPI (for nuclei) was used to evaluate the percentage of CNFs in the muscles. 
Whilst 85.3±1.4% CNFs were detected in TA of untreated mdx mice, administration of BPMO-M23D 
resulted in a statistically not significant decrease to 77.2±3.7% CNFs (p=0.07, Student t-test) in the 
treated muscles. Co-injection of BPMO-M23D and BPMO-MSTN reduced significantly CNFs to 
74.8±2.9% (p <0.05) (Figure 4A) as compared to TA muscles of saline treated mdx mice. In DIA 
muscles of saline-treated mdx mice, only 5.9±0.4% CNFs were detected probably because this muscle 
is severely affected and the majority of damaged myofibres had been replaced by fibrotic tissue at the 
examination time. Thereby, we observed minor non-significant alterations in the percentage of CNFs 
following delivery of either BPMO-M23D or BPMO-M23D+MSTN in DIA muscle (Figure 4B). The 
amount of fibrosis in TA, DIA and GAS muscles of treated mice was further analysed by measuring 
the area covered by the staining of muscle sections for Collagen VI and by Sirius red solution for 
detecting Collagen I and III. In TA muscles, treatment with BPMO-M23D or with the combination of 
the 2 BPMOs significantly reduced the amount of Sirius red positive area from 7.2±0.8% (in saline-
treated mdx mice) to 3.9±0.4% (p<0.05) and 4.4±0.5% (p<0.01) respectively (Figures 4C, E). 
Collagen VI staining was also reduced from 10.8±0.6% (in saline-treated mdx mice) to 6.5±0.7% 
(p<0.01) and 6.2±0.6% (p<0.001) (Figures 4D, E). In DIA muscle, where the area covered by 
connective tissue was substantially larger (52.1±2.8% of the total area in saline-treated mdx mice), 
BPMO-M23D or the combined treatment significantly reduced the collagen I and III expression to 
39.5±1.9% (p<0.05) and 39.9±1.3% (p<0.001) respectively while only a statistically not significant 
decrease was observed for Collagen VI (p=0.07 and 0.08 with BPMO-M23D and the combined 
BPMOs respectively, unpaired t-test) (Figures 4F-H). In GAS muscles, that show an intermediate 
fibrotic pathological deposition, treatment with BPMO-M23D or with the combination of the 2 
BPMOs significantly reduced the amount of Sirius red detected area from 25.2±2.1% (in saline-
treated mdx mice) to 17.2±1.8% (p<0.05) and 17.8±1.3% (p<0.05) respectively (Supplementary 
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Figures 1A, C). Collagen VI expression was also reduced from 21±1% (in saline-treated mdx mice) 
to 13.3±1.1% (p<0.001) and 12.9±0.4% (p<0.001) respectively (Supplementary Figures 1B, C). 
 
In order to evaluate the benefit of antisense treatment on muscle function, both a grip strength test to 
assess the forelimb strength and an in situ muscle electrophysiology to examine the function of 
isolated TA muscle were performed. The force generated by the forelimbs was normalised to the final 
bodyweight of the mice. Aged mdx mice had significantly weaker forelimbs compared to those of 
age-matched C57BL/10J mice (20.7±0.6 mN/g of body weight in C57 mice versus 10.7±0.6 mN/g in 
mdx mice, p<0.001). Treatment with either BPMO-M23D (18.1±0.6 mN/g) or with the BPMO 
cocktail (18±0.5 mN/g) normalised the forelimb muscle force to the level of C57 mice (p<0.001 in 
both cases, Figure 5A). In situ TA muscle force measurement, by electrophysiology analysis, 
indicated that in mdx mice the specific maximal force (i.e. the maximal force generated by the muscle 
after 150Hz stimulation normalised by the muscle weight) was almost half of the level measured in 
C57BL/10J mice (11.3±1.0 N/g in mdx mice versus 21.5±1.2 N/g in C57 mice, p<0.001). A trend 
towards an increase in specific maximal force was observed after treatment with either BPMO-M23D 
(15.2±0.8 N/g p=0.01, student t-test) or the combination of the BPMOs (14±0.7 N/g p=0.05, student t-
test) (Figure 5B). Furthermore, untreated dystrophic muscles were susceptible to muscle damage and 
displayed a clear force drop following 9 eccentric contractions. The treatment with BPMO-M23D 
slightly improved the resistance to the eccentric contractions (from 31% to 43% of the initial maximal 
force, p=0.1791) whilst muscles of mice treated with the cocktail of BPMOs were substantially 
protected from the damage, with a resistance to eccentric contraction of about 73% of the initial 
maximal force (p<0.001) (Figure 5C).  
 
These data show that chronic systemic injection with either BPMO-M23D or, more substantially, with 
BPMO-M23D+MSTN restores dystrophin expression at the level that significantly improves some 
aspects of the histopathology and function in TA and GAS muscles of old mdx mice. Of importance, 
the treatment is sufficient in DIA muscle to significantly decrease the content in collagen I and III 
despite its severe pathology. 
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Discussion 
Exon skipping of DMD pre-mRNA has been considered a valuable approach for the treatment of 
DMD. A number of clinical trials based on 2'-OMePS or PMO chemistry of AON has been 
conducted, leading to the conditional approval of a PMO called Eteplirsen by the FDA for DMD 
treatment. However, while AON therapy targeting the restoration of dystrophin offers potential 
therapeutic benefit, additional adjunct therapies could further enhance the efficacy of the treatment.   
 
We recently described the promising effects of the antisense approach combining dystrophin and 
myostatin exon splice modulation in dystrophic mice at 2 different stages of the disease (8, 18, 19). 
We showed that in both neonatal mice (from postnatal day 0) where the muscle pathology is not 
developed and in juvenile mice (from 6-week old) where the disease is dramatically progressed, the 
dual BPMO treatment restoring dystrophin and inhibiting myostatin expression has beneficial effects 
on respectively preventing or significanly attenuating most of the features of the disease. Here we 
report and confirm these positive effects in aged mdx mice (from 15-month old), where the pathology 
is significantly more severe and more similar to the one affecting DMD boys (21, 23). To our 
knowledge AON-cell penetrating peptide conjugates have never been tested in such a model that is 
both a genocopy and a more trustable representative phenocopy of DMD. Here we confirm that: (1) 
BPMO-M23D administration restores dystrophin protein expression in aged mdx mice; (2) The dual 
antisense treatment improves the effect of the single dystrophin exon skipping approach.  
 
In recent years, targeting the myostatin signaling pathway has become an attractive approach to treat 
muscle atrophy. In DMD, it has been suggested that myostatin knockdown could enhance muscle 
mass and muscle strength, and reduce muscle fibrosis in mdx mice (17, 24). The most advanced 
approach to knock down myostatin is based on the use of antibodies to block the protein (i.e. 
Domagrozumab). However in a recent phase II clinical trial in DMD boys, this approach failed to 
fulfill the clinical endpoints and was terminated (https://www.pfizer.com/news/press-release/press-
release-
detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duche
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nne_muscular_dystrophy). The use of AONs to disrupt MSTN pre-mRNA has an advantage over 
protein blockage therapies as AONs are designed to target specifically the sequence of the MSTN 
gene. Therefore, antisense approaches are selective to myostatin and can minimize off-target side-
effects observed in protein blockage therapies, which potentially occur due to unexpected targeting of 
other members of the TGF-β family (i.e. activin) (25). Skeletal muscle-derived myostatin undergoes 
complex post-translational modification to maintain the balance of mature/precursor protein in the 
bloodstream. Once this balance is disrupted, i.e. by exogenous compounds, precursor myostatin in its 
latent form can be activated to regain the balance, diminishing the therapeutic benefit (26). It has been 
also reported that circulating myostatin level is dependent on both the type of muscle dystrophies and 
the disease stages (22). Mariot et al showed that in atrophic muscles (i.e. of DMD patients) the 
myostatin level was significantly reduced compared to healthy individuals, probably to counteract the 
muscle wasting process (22). This was confirmed by ELISA quantification of blood serum myostatin 
and RT-qPCR for Mstn mRNA expression in our treated mice that potentially explains the lower 
therapeutic effect we observed in aged mice, as compared to the levels seen previously in young mice 
(8, 18, 19). An alternative, but not mutually exclusive, explanation is that the highly fibrotic 
deposition in muscles of aged mdx mice further hampers the AON delivery. Indeed substantial fibrotic 
tissue was detected in muscles of saline-treated aged mice and particularly in the gastrocnemius and 
the diaphragm. This was significantly reduced in tibialis anterior and gastrocnemius muscles with 
BPMO treatments but only marginally attenuated in the more affected diaphragm. However, we 
previously showed that one-year treatment with unconjugated PMO-M23D significantly reduced the 
fibrosis also in the diaphragm (27), suggesting that a longer-term treatment with combined BPMOs 
would likely be more effective in reducing fibrosis. Therefore if the lower efficacy observed in aged 
mice compared to younger animals is due to the fibrosis deposition, starting early a long-term 
treatment with BPMOs could significantly improve the dystrophin expression in the medium-long 
term.  
 
Although myostatin inhibition is not efficient enough to increase the muscle mass as seen in neonatal 
and juvenile dystrophic mice previously (18, 19), in the dual approach it remains sufficient to improve 
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dystrophin production with muscles of mice treated with the combination of BPMOs consistently 
expressing more dystrophin than muscles of mice treated with only BPMO-M23D. Since inhibition of 
myostatin upregulates the Akt/mTOR/p70S6K protein synthesis pathway (28, 29), the synthesis rate 
of cytoplasmic proteins like dystrophin is potentially increased when a dystrophin restorative strategy 
such as the BPMO-M23D is co-delivered. An increased dystrophin expression could have a 
significant impact on stability of myofibre integrity and then on muscle regeneration and finally in 
fibrosis deposition as we indeed observed. Importantly, despite being less effective than in neonatal or 
juvenile mice, the combined antisense therapy improved dystrophin expression in diaphragm and 
heart muscles where the single BPMO-M23D treatment failed to induce a detectable dystrophin 
expression. Since most DMD patients die from cardiac and respiratory failure (6), dystrophin recovery 
in respiratory and cardiac muscles has obvious clinical relevance. The beneficial effects of the 
combined treatment were further confirmed by the fact that forelimb strength was significantly 
improved after treatment. As we did not measure the strength at the initial baseline and we observed a 
decrease in bodyweight of untreated mdx mice we cannot rule out that the treatments actually 
prevented a decrease in muscle force more than increased the strength of the mice. Notably, the 
observation that the function of the hindlimb muscles was protected from damaging muscle 
contractions only when the muscle received the combined treatment likely reflects the enhanced 
dystrophin expression in muscles of mice treated with the combined BPMOs. These results 
demonstrate that even in a challenging environment where the disease is in an advanced stage, as in 
the muscles of aged mdx mice, the combined antisense approach is beneficial and more effective than 
skipping dystrophin alone with BPMO-M23D. This further confirms the potential benefits of such 
treatment, hence suggesting possible favourable effects of a combined AON approach in clinical 
scenario for DMD treatment.  
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Materials and methods 
 
PMOs and PMO conjugates 
Both PMOs for dystrophin (5′-GGCCAAACCTCGGCTTACCTGAAAT-3′) and MSTN (5′-
CAGCCCATCTTCTCCTGGTCCTGGGAAGGT-3′) skipping were prepared and conjugated to an 
arginine-rich cell-penetrating peptide (so-called B-peptide: RXRRBRRXRRBRXB) at the 3’-end of 
the PMOs by Sarepta Therapeutics, Inc. (Cambridge, Massachusetts, USA). M23D sequence binds to 
the donor splice site of Dmd exon 23 (+07 –18) (30). Sequence to skip Mstn exon 2 binds to an exonic 
splicing enhancer within the exon (+30 +1) (31). BPMOs were solubilized in ddH2O and diluted in 
sterile 0.9% saline (Sigma, Dorset, UK) before injection.  
 
Animals and experimental design 
Ethical and operational permission for in vivo experiments was granted by the RHUL Animal Welfare 
Committee and the UK Home Office. This work was conducted under statutory Home Office 
regulatory, ethics, and licensing procedures, under the Animals (Scientific Procedures) Act 1986 
(Project Licence 70/8271). 16 mdx (C57BL/10ScSn-Dmdmdx) and 6 C57BL/10J (Jax strain 000665) 
male mice were bred in house and maintained in a standard 12-hour light/dark cycle with free access 
to food. Fifteen to twenty-month old mice were randomized based on the age before the first injection. 
C57 mice were 15.0±1.0 month-old while the mean age of mdx group treated with saline, BPMO-
M23D or the combination of BPMOs was 16.6±0.5, 16.8±2.0 and 17.6±2.0 month-old, respectively. 
Five mdx mice were injected with 200 µl of sterile saline containing either 10 mg/kg BPMO-M23D, 
or a combination of 10 mg/kg BPMO-M23D and 10 mg/kg BPMO-MSTN. Groups of 6 age-matched 
mdx or C57BL/10J mice were weekly injected with 200 µl of sterile saline. Mice were weighed and 
tail vein injected weekly for 10 consecutive weeks. Amounts of BPMOs were adjusted accordingly 
for the weekly injections. One week after the last injection, forelimb muscle force was evaluated by 
grip strength tests. In situ muscle force analysis and tissue collection were performed 2 weeks after 
the last injection. 
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Tissue collection  
Diaphragm (DIA), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL), tibialis 
anterior (TA), and heart were collected from treated mice soon after contractile measurements. 
Tissues from one side of the body were frozen immediately in liquid nitrogen for RNA and protein 
extraction whilst tissues from the other side were embedded in optimal cutting temperature medium 
(VWR, Leicestershire, UK) and frozen in liquid nitrogen-cooled isopentane (Sigma, Dorset, UK) for 
cryosectioning. All samples were kept at -80oC until use.  
 
RNA extraction and RT-PCR/qPCR quantifying exon skipping efficiency  
RNeasy Fibrous Tissue kit (QIAgen, Manchester, UK) was used in RNA extraction as previously 
described (19). Briefly, tissue was homogenized using a TissueLyser II (QIAgen, Manchester, UK) 
and the total RNA was extracted following the manufacturer's instructions. A ND-1000 NanoDrop 
spectrophotometer (Thermo Scientific, Leicestershire, UK) was used for RNA quantification. 
GoScript Reverse Transcription System (Promega, Southampton, UK) was used to reverse transcribe 
500 nanograms of RNA in a reaction supplemented with 0.5 µg oligo d(T)16 (Thermo Scientific, 
Leicestershire, UK) and 0.5 µg random primer (Thermo Scientific, Leicestershire, UK), and run at 
25oC for 5 min, 42oC for 1 hour and 72oC for 15 min. Four microliters of cDNA products were used 
as templates in semi-nested (dystrophin) or nested (myostatin) PCRs and were amplified by GoTaq 
Polymerase (Promega, Southampton, UK) using PCR programs: 94°C for 2 min, 30 cycles at 94oC for 
1 min, 57oC/54oC for 1 min for semi-nested Dmd or 56oC/57oC for 1 min for nested Mstn, 72oC for 45 
sec, and final extension at 72°C for 5 min. The final PCR products were loaded onto 2% agarose gels. 
HyperLadder IV (Bioline, London, UK) was used as a size marker. Samples were loaded in the same 
order in gels showing Dmd and Mstn exon skipping and for the western blot showing dystrophin 
expression. GeneTools Image Analysis software 4.02 (Syngene, Cambridge, UK) was used to perform 
densitometric analysis of gel electrophoresis. The efficiency of dystrophin or myostatin exon skipping 
was evaluated as the percentage of the density of skipped products against the total density of 
unskipped and skipped products. In qPCR for Mstn mRNA, cDNA was diluted at 1:20 in qPCR water 
(Roche, UK). Ten nanograms of diluted cDNA were then amplified using LightCycler480 SYBR 
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Green Master I kit (Roche, UK), according to the manufacturer’s instructions. Samples were prepared 
in triplicates. Reactions were run on LightCycler480 System, initialised at 95oC for 5 min, followed 
by 45 cycles at 95oC for 15 sec, 60oC for 15 sec, 72oC for 15 sec. Relative quantification was 
performed against corresponding Gapdh housekeeping gene. 
 
Protein extraction and western blot quantifying dystrophin expression 
Immunoblot was previously described (19). Briefly, tissue was homogenized on a TissueLyser II 
(QIAgen, Manchester, UK) at 25 Hz for 2 x 2 min. After centrifugation (13,000 rpm, 10 min, 4oC), 
the supernatant was transferred to freshly pre-chilled 1.5 ml tubes and the total protein was quantified 
by DC Protein Assay (Bio-Rad, Hertfordshire, UK) using the manufacturer's instructions. Protein 
samples (100 µg) were loaded on 3-8% Tris Acetate NuPage gels (Life Technologies, Paisley, UK). 
HiMark Pre-stained Protein Ladder (Life Technologies, Paisley, UK) was used as a size marker. Gels 
were run at 150 V for 1.5 h and transferred in NuPage transfer buffer (Life Technologies, Paisley, 
UK) mixed with 10% methanol (Sigma, Dorset, UK) to HyBond nitrocellulose membranes (GE 
Healthcare, Little Chalfont, UK) at 30 V for 2 h. After blocking (in 5% skimmed milk, 1X PBS, 0.2% 
Tween-20 for 1 h), membranes were incubated overnight at 4oC with either monoclonal mouse anti-
dystrophin 6C5 (1:100, Novocastra Laboratories, Newcastle upon Tyne, UK) or mouse anti-GAPDH 
(1:10000, Abcam, Cambridge, UK) antibody. Then membranes were incubated with secondary 
antibody (1:10000, LI-COR Biosciences, Cambridge, UK), goat anti-mouse IRDye800 or goat anti-
rabbit IRDye680. The blots were visualised on an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Cambridge, UK). To perform protein quantification, a mix of wild-type and mdx proteins 
to provide 0, 5, 10, 20, 40, 60, 80% of wild-type dystrophin protein was loaded in a 3-8% Tris Acetate 
gel. Densitometric analysis was performed using ImageJ software (NIH, Bethesda, Maryland, USA) 
and dystrophin positive bands were normalised to the values of corresponding GAPDH intensity and 
then protein expression was calculated using the standard curve made by the set of samples with 
increasing wild-type dystrophin protein concentrations. All reagents were from Sigma (Dorset, UK), 
unless stated otherwise. 
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Immunostaining, histology and quantification 
After cryosectioning on an OTF 5000 cryostat (Bright, Huntingdon, UK), sections (10-µm thickness) 
were kept at -80oC until use. For the co-immunostaining for dystrophin and laminin, sections were 
fixed in ice-cold acetone for 10 min and blocked in 1% BSA, 1% goat serum, 0.1% Triton X-100, 1x 
PBS. Sections were then incubated with rat anti-laminin antibody (1:1000, Sigma, Dorset, UK) and 
rabbit anti-dystrophin H12 (Dys2, 1:100, (32)) antibody at 4oC, overnight. Slides were washed three 
times in PBS, 0.05% Tween-20 and then incubated with goat anti-rat Alexa568 and goat anti-rabbit 
Alexa488 (1:200, Life Biotechnologies, Paisley, UK). For Collagen VI immunostaining, rabbit anti-
Collagen VI monoclonal antibody was used (1:400, Abcam, Cambridge, UK for 1h, RT) followed by 
3 washings and incubation with secondary antibody goat anti-rabbit Alexa488 (1:200, Life 
Biotechnologies, Paisley, UK). An additional 15 min staining with 1 µg/ml 4′,6-diamidino-2-
phenylindole (DAPI, Sigma, Dorset, UK) was performed prior to mounting in Mowiol 4-88 (Sigma, 
Dorset, UK). Co-staining of laminin and DAPI was used to quantify the % of centrally nucleated 
fibres. A standard protocol for PicroSirius red staining was followed to detect Collagen I and III 
proteins. Immunostaining for dystrophin/laminin, laminin/DAPI and for collagen VI were visualised 
under an epifluorescence Olympus microscope. Six non-overlapping random images at 200x 
magnification were captured in the largest section of each muscle. For dystrophin-positive fibre 
staining, counting was performed manually using ImageJ software (NIH, Bethesda, Maryland, USA). 
Only fibres showing a bright and continuous staining of dystrophin around the sarcolemma were 
considered as dystrophin-positive. The percentage of positive fibres was calculated by dividing these 
values by the number of laminin positive fibres within the same image field. An average of 1200 DIA 
and 1100 TA fibres per animal was scored. ImageJ software was also used to calculate the area of 
each image covered by collagen VI or by Sirius red staining. The percentage of area covered by 
fibrotic tissue was calculated by dividing these values by the total area of the field. All analyses were 
performed blinded by a single operator.  
 
Measurement of forelimb strength  
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The forelimb strength was assessed using a commercial grip strength monitor (Linton 
Instrumentation, Norfolk, UK). Measurements were performed 5 times per mouse over a 3-day 
period. Mice were held by the tail, allowed to grasp a metal mesh attached to a force transducer with 
their forelimbs. Mice were gently pulled until they released the grip and force was recorded. Thirty-
seconds were elapsed between each of 5 sequential tests per mouse per each day. Data were expressed 
as gram force per gram of the final body weight. 
 
In situ tibialis anterior muscle force measurement 
Mice were anesthetized by intraperitoneal injection of pentobarbital solution (60 mg/kg). Contractile 
properties of TA muscles were analyzed as previously described (33, 34). Briefly the knee and foot of 
the mouse were fixed with clamps and the distal tendon of the muscle was attached to an isometric 
transducer (Dual-mode muscle lever, Aurora scientific, Aurora, Canada) using a silk ligature. The 
sciatic nerve was isolated and distally stimulated by a bipolar silver electrode using supramaximal 
square wave pulses of 0.1 ms duration. All data provided by the isometric transducer were recorded 
and analyzed using the Dynamic Muscle Control and Analysis Software (Aurora scientific, Aurora, 
Canada). Isometric measurements were made at an initial length L0 (length at which maximal tension 
was obtained during the tetanus). Response to tetanic stimulation (pulse frequency: 150 Hz) was 
recorded and the maximal force was determined. For the study of the muscle resistance to eccentric 
contraction, a lengthening of 15% of muscle was applied for 9 consecutive stimulations at 150Hz. 
Maximal (isometric) force generated after each eccentric contraction is expressed as percentage of to 
the initial maximal force. Blind analyses were performed by the operator.  
 
Statistical analysis 
GraphPad Prism5 software (San Diego, California, USA) was used for statistical analyses. All data 
are shown as the means ± S.E.M; One-way ANOVA followed by Bonferroni's post-hoc test or by 
two-tailed Student’s t-test was used to assess the statistical significance. Significant levels were 
considered at *p < 0.05, **p < 0.01, ***p < 0.001.  
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Legends to figures 
 
Figure 1: Dystrophin restored by BPMO-M23D or the combined BPMO delivery reduces body loss 
in aged mdx mice but has no effect on muscle weight. (a) Body weight, assessed weekly and 
normalised to the initial weight, indicates that both the BPMO-M23D and the combined BPMO 
treatments reduced the loss of body weight compared to mice treated with saline. (b) Muscle mass of 
diaphragm (DIA), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL) and tibialis 
anterior (TA) measured after sample collection was unchanged after BPMO treatments. Data are 
expressed as means ± S.E.M; n = 5-6 per group. Statistical analysis was two-tailed Student’s t-test and 
comparisons were with mdx untreated group. Significant levels were set at *p < 0.05, **p < 0.01, 
***p < 0.001.  
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Figure 2: BPMO-M23D treatment induces efficient exon skipping of dystrophin and body-wide 
dystrophin restoration that is enhanced by co-delivery of BPMO-MSTN. (a) Semi-nested dystrophin 
RT-PCR products from diaphragm (DIA), extensor digitorum longus (EDL), gastrocnemius (GAS), 
soleus (SOL) and tibialis anterior (TA) and Heart were loaded on 2% agarose gels. Each lane displays 
the result from an individual muscle. C57, mdx and no template RT-PCR controls for DIA and TA are 
also shown. HyperLadder IV was used as a molecular size marker. Exons included in each band of 
PCR products are shown to the left of the gels. (b) Levels of exon skipping in each muscle type and 
averaged skipping of all muscles observed after the different BPMO treatments are displayed. The 
skipping efficiency for dystrophin, evaluated using densitometric analysis of RT-PCR products, is 
expressed as percentage of the density of skipped products compared to the density of the sum of 
skipped and unskipped products. (c) Western blot analysis in DIA, EDL, GAS, SOL, TA, and Heart 
muscles shows dystrophin expression after BPMO-M23D and combined BPMO-M23D+MSTN 
treatment in mdx mice. Each lane is a sample from an individual mouse. Proteins from type-matched 
muscle of saline-injected C57 and mdx mice were loaded as controls. GAPDH was used as loading 
control for western blot. (d) The intensity of dystrophin bands was quantified and normalised to the 
intensity of the corresponding GAPDH band. Results, expressed as percentage of C57 values obtained 
using a wild-type standard curve, show that the co-delivery of BPMOs enhanced the dystrophin 
expressed by the single BPMO-M23D treatment. Results of individual muscle types and the average 
of all muscles are shown. (e) Representative images of immunostaining for dystrophin (green) and 
laminin (red) expression in TA and DIA muscles are shown. Nuclei were counterstained with DAPI 
(blue). Scale bar: 200 µm. (f, g) The percentage of dystrophin positive fibres detected after 
immunostaining was quantified and expressed as percentage of laminin positive fibres. Statistical 
comparison was two-tailed Student's t test in b and d and one-way Anova test with Bonferroni post-
hoc test in f and g; **p < 0.01, ***p < 0.001.  Data are expressed as means ± S.E.M; n = 5 per group.  
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Figure 3: Chronic systemic delivery of BPMOs induces detectable exon skipping of myostatin. (a) 
Nested myostatin RT-PCR products from diaphragm (DIA), extensor digitorum longus (EDL), 
gastrocnemius (GAS), soleus (SOL), tibialis anterior (TA) and heart were loaded on 2% agarose gels. 
Each lane shows the result from an individual muscle. HyperLadder IV was used as a molecular size 
marker. Exons included in each band of PCR products are shown to the right of the gels. (b) Levels of 
exon skipping in each muscle types and averaged skipping of all muscles observed after the BPMO 
treatment are displayed. The skipping efficiency for myostatin, evaluated using densitometric analysis 
of RT-PCR products, is expressed as percentage of the density of skipped products compared to the 
density of the sum of skipped and unskipped products. (c) ELISA of circulating myostatin protein in 
blood serum collected from treated and untreated mice. (d) Real time RT-PCR detecting Mstn mRNA 
in DIA muscles, normalised to the Gapdh expression. (e) Real time RT-PCR detecting Mstn mRNA in 
TA muscles, normalised to the Gapdh expression. Data are expressed as means ± S.E.M; n = 5 per 
group. In (b-e) statistical analysis was one-way Anova test with Bonferroni post-hoc test, *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 4: BPMO administration improves histopathological and functional features of dystrophic 
muscles. (a, b) Immunofluorescence staining for laminin and DAPI was used to quantify the 
percentage of fibres with one or more central nuclei (CNF: centrally nucleated fibres). Five random 
fields per muscle were analysed. Results are expressed as percentage of the total fibres. (c-h) Sirius 
red staining and immunostaining for collagen VI were performed to evaluate muscle fibrosis in 
sections of treated tibialis anterior (TA) and diaphragm (DIA) muscles. Scale bar: 200 µm. The area 
covered by the staining was quantified and analysed with NIH ImageJ. Both BPMO-M23D and the 
co-delivery of BPMOs reduced collagen deposition in TA (c-d) and DIA (f-g) muscles. (e, h) 
Representative images were captured in the largest sections of treated muscles. Data are shown as 
means ± S.E.M; n = 5-6 per group. Statistical comparison was one-way Anova test with Bonferroni 
post-hoc test in (a-d) and (f, g); *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant.  
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Figure 5: BPMO administration improves contractile properties of dystrophic muscles 
(a) Forelimb muscle force was evaluated by grip strength test, normalised to the final body weight and 
expressed as gram force per gram of body weight. Results show that dystrophin produced by either 
BPMO-M23D or the co-delivery of BPMOs improves muscle strength in treated mice. (b) In situ 
tibialis anterior (TA) muscle physiology was performed in treated mice under terminal anesthesia. 
Treatment with BPMOs induces small changes in the specific maximal force detected in TA muscles. 
(c) Resistance to the damage provided by 9 consecutive eccentric contractions was significantly 
increased after treatment with the combination of BPMO-M23D and BPMO-MSTN. * and # are used 
to show statistical difference between mdx and C57 mice or mdx and combined BPMOs treatment 
respectively. Data are presented as means ± S.E.M; n = 5-6 per group. Statistical comparison was one-
way ANOVA test with Bonferroni's post-hoc test; ***p < 0.001, ###p < 0.001, #p < 0.05, ns: not 
significant. 
 
 
Abbreviations 
DMD: Duchenne muscular dystrophy 
MSTN: myostatin 
PMO: phosphorodiamidate morpholino oligomer 
AON: Antisense oligonucleotides 
CNF: Centrally nucleated fibres 
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TA: tibialis anterior 
DIA: diaphragm 
EDL: extensor digitorum longus 
SOL: Soleus 
GAS: Gastrocnemius  
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